2B70:F:F-iShares NASDAQ US Biotechnology UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 5.977

Change

+0.06 (+0.95)%

Market Cap

USD 0.52B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Sell

ducovest Verdict
Created with Highstock 5.0.6

Very Bearish

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
2B70:F
Relative Returns (From:    To: 2025-03-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

-6.54 (-1.18%)

USD 108.00B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.42 (-0.81%)

USD 105.67B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.46 (-0.80%)

USD 104.83B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.11 (-0.72%)

USD 62.86B
VUSA:F Vanguard Funds Public Limited ..

-1.62 (-1.63%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-2.00 (-0.85%)

USD 49.04B
XJSE:F Xtrackers II - Japan Governmen..

-0.02 (-0.24%)

USD 41.48B
0ZC:F Zscaler Inc

-3.56 (-1.91%)

USD 37.92B
BSND:F Danone SA

-0.30 (-2.13%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-0.40 (-0.32%)

USD 24.77B

ETFs Containing 2B70:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.08% 48% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.08% 48% F 52% F
Trailing 12 Months  
Capital Gain 3.00% 41% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.00% 38% F 45% F
Trailing 5 Years  
Capital Gain 47.18% 36% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.18% 37% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain 4.43% 48% F 51% F
Dividend Return 4.43% 45% F 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.90% 53% F 85% B
Risk Adjusted Return 34.38% 42% F 55% F
Market Capitalization 0.52B 61% D- 48% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.